Clinical Trial Detail

NCT ID NCT03365791
Title PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

sarcoma

lymphoma

Advanced Solid Tumor

neuroendocrine tumor

diffuse large B-cell lymphoma

gastric adenocarcinoma

esophagus adenocarcinoma

ovary adenocarcinoma

lung small cell carcinoma

prostate adenocarcinoma

Therapies

LAG525

Spartalizumab

Age Groups: adult senior

No variant requirements are available.